timothy sykes logo
KOD Stock Jumps As Phase 3 Data Catalyst Looms Thumbnail
G Google News

KOD Stock Jumps As Phase 3 Data Catalyst Looms

ELLIS HOBBS•UPDATED SEP. 28, 2026, 7:48 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Kodiak Sciences Inc surged as stocks have been trading up by 69.18 percent following highly positive clinical trial news

Key Takeaways

  • UBS reiterates a Buy on Kodiak Sciences with an $80 price target versus the current roughly $31 KOD share price, pointing to major upside if key trials deliver.
  • Upcoming phase III wet AMD trials for tarcocimab and KSI-501 are expected by UBS to show non-inferiority to Eylea with longer dosing intervals, after a recent KOD pullback.
  • Goldman Sachs resumes coverage of Kodiak Sciences at Neutral with a $36 target, citing a stronger biotech backdrop driven by M&A, clinical wins, and easier regulation.
  • Pivotal Phase 3 DAYBREAK topline results for Zenkuda (tarcocimab tedromer) and KSI-501 in wet AMD are due on 2026/09/28, putting Kodiak Sciences at the center of retina trading.

Candlestick Chart

Live Update At 07:47:48 EDT: On Monday, September 28, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 69.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Kodiak Sciences, trading as KOD, is acting like a classic biotech catalyst name. The multi-day chart shows the stock drifting in the low-to-mid $30s, with closes between about $31 and $36 over recent sessions. That range tells traders KOD has already re-rated higher, but not gone parabolic yet.

The intraday 5‑minute tape is a different story. KOD exploded from the low $30s to the mid‑$50s in early premarket, hitting highs above $58 before fading. That type of spike-and-pullback action screams event-driven speculation, with traders piling in ahead of the 2026/09/28 DAYBREAK readout and analyst commentary from UBS and Goldman.

More Breaking News

Fundamentally, Kodiak Sciences is still a development-stage biotech. Recent quarterly numbers show a net loss of about $65.6M and negative free cash flow around $46.6M, backed by roughly $125.9M in cash. Returns on equity and assets are deeply negative, which is normal at this stage but underscores that KOD is a clinical-data and capital-markets story, not a cash generator yet. With a price-to-book above 30 and a current ratio of 2.5, traders are clearly paying for retina pipeline potential, not current earnings.

Why Traders Are Watching KOD Into Phase 3 Data

KOD is on a tight clinical and news calendar, and that’s exactly what momentum traders want. UBS just reiterated a Buy rating on Kodiak Sciences with an $80 price target, more than double the recent ~$31 level. The firm leans heavily on upcoming phase III wet AMD trials for tarcocimab and KSI‑501, expecting non-inferiority to Eylea and possibly longer dosing intervals. In plain English, if Kodiak Sciences can match a blockbuster drug while cutting down injections, that is a big commercial hook.

On top of that, UBS points to a cluster of catalysts: September topline data, an American Academy of Ophthalmology presentation in October, and more data in December. For short-term KOD trading, that means a string of events where sentiment can flip fast. Each data drop is a potential gap-up or gap-down.

Then there’s the broader backdrop. Goldman Sachs has resumed coverage of Kodiak Sciences with a Neutral rating and a $36 target, tying the story into a biotech sector they say is already outperforming thanks to M&A, clinical wins, and friendlier regulators. That more cautious stance reminds traders that not every big bank sees an $80 path here. Execution risk and valuation still matter.

Layer the fundamentals on top and KOD looks like a text-book high-risk, high-reward biotech. Heavy R&D spend near $56.1M for the quarter, negative earnings per share of about -$1.05, but a sizable cash cushion around $132.1M at quarter-end give Kodiak Sciences runway to reach these readouts. For active traders, the message is simple: KOD’s chart and news flow are both primed for volatility.

Conclusion

Kodiak Sciences is stepping into a make-or-break window. The Phase 3 DAYBREAK topline readout on 2026/09/28 for Zenkuda (tarcocimab tedromer) and KSI‑501 in wet AMD is the core catalyst that can reprice KOD in a single session. Positive data would back UBS’s bullish $80 call and justify the recent surge from the low $30s into the $50s intraday. Weak or ambiguous data, and traders who chased KOD late risk getting trapped.

At the same time, KOD is not a one-day story. The company is lining up additional Phase 3 readouts in other retinal indications and a key AAO presentation. That creates a series of tradable moments where sentiment on Kodiak Sciences can swing sharply, and where disciplined traders can look for breakouts, failed breakouts, and panic dips.

Goldman’s Neutral view and $36 price target serve as an important speed bump. They signal that, even with sector tailwinds, Kodiak Sciences still needs to prove its case in the clinic and, later, in the market. For traders, that means respecting both sides of the tape and sizing accordingly.

Or as Tim Sykes likes to hammer home, “The market doesn’t care about your opinion, it cares about price action and catalysts. Study the chart, study the news, and always be ready to cut losses fast.” As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. KOD now offers both powerful news catalysts and wild price action — a combination that rewards preparation and punishes complacency.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”